The Oncology Institute, Inc. shares rise 1.58% after-hours following Citius Oncology's AI platform deployment for LYMPHIR™ therapy.
ByAinvest
Friday, Aug 22, 2025 4:44 pm ET1min read
TOI--
The Oncology Institute, Inc. rose 1.58% in after-hours trading. Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, Inc., announced the deployment of an AI platform to support its commercial team with advanced data analytics and insights ahead of the anticipated launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL). The platform is designed to strengthen decision-making and refine targeting, which could positively impact the stock price.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet